HOUSTON, Nov. 18, 2021 /PRNewswire/ -- Marker
Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications, today
announced that data from a Phase 1 study investigating its
MultiTAA-specific T cells were selected for oral presentation at
the 2021 American Society of Hematology (ASH) Annual Meeting. The
results will be reviewed by investigators at the Baylor College of Medicine, Marker's research
partner. ASH will take place from December
11-14, 2021, in Atlanta and
in a virtual format.
Oral Presentation Details
Presentation Title: Donor-Derived Adoptive T-Cell
Therapy Targeting Multiple Tumor Associated Antigens to Prevent
Post-Transplant Relapse in Patients with ALL (Abstract #471)
Session Title: 704. Cellular Immunotherapies: Cellular
Therapies for ALL
Session Date/Time: Sunday, December 12, 2021,
12:30 p.m. ET
Presenting Author: Dr. Swati
Naik, MBBS, Center for Cell and Gene Therapy, Baylor College of Medicine
Location: Georgia World Congress Center, B401-B402 and
virtual
The abstract is available on the American Society of
Hematology 2021 Annual Meeting website and in a supplement to the
November issue of Blood, an ASH journal.
About Marker Therapeutics, Inc.
Marker Therapeutics,
Inc. is a clinical-stage immuno-oncology company specializing in
the development of next-generation T cell-based immunotherapies for
the treatment of hematological malignancies and solid tumor
indications. Marker's cell therapy technology is based on the
selective expansion of non-engineered, tumor-specific T cells that
recognize tumor associated antigens (i.e. tumor targets) and kill
tumor cells expressing those targets. This population of T cells is
designed to attack multiple tumor targets following infusion into
patients and to activate the patient's immune system to produce
broad spectrum anti-tumor activity. Because Marker does not
genetically engineer its T cell therapies, we believe that our
product candidates will be easier and less expensive to
manufacture, with reduced toxicities, compared to current
engineered CAR-T and TCR-based approaches, and may provide patients
with meaningful clinical benefit. As a result, Marker believes its
portfolio of T cell therapies has a compelling product profile, as
compared to current gene-modified CAR-T and TCR-based
therapies.
To receive future press releases via email, please visit:
https://www.markertherapeutics.com/email-alerts.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/marker-therapeutics-announces-that-data-from-investigator-sponsored-phase-1-study-with-its-multitaa-specific-t-cells-to-be-presented-at-the-2021-american-society-of-hematology-annual-meeting-301428592.html
SOURCE Marker Therapeutics, Inc.